生命起源中的主体生成与层次跃迁，肿瘤耐药演化、抗肿瘤药物转化
仇玮祎，北京集智会自然科学研究中心研究员。2003年本科毕业于扬州大学畜牧兽医学院，2006年于军 事医学科学院获得预防兽医学硕士学位，2009年于军事医学科学院获得肿瘤分子遗传学博士学位。 2009-2019年于军事医学科学院（后转隶为军事科学院）从事治疗性抗体药物研发工作，曾作为骨干参 与抗肿瘤抗体药物安美木单抗（II期）等药物的临床前研究和IND申报。
文章发表节选
WY Qiu, S Wang, C Zhang, XY Yu, JL Ma, P Du, YQ Zheng, B Pang, XB Pang, ZW Sun. A novel antiEGFR mAb Ame55 with lower toxicity and better efficacy than cetuximab when combined with Irinotecan. J Immunol Res. 2019 Jan 13;201.
W. Qiu, S. Wang. A Study on the Low Toxicity and High Efficacy of a Novel Fully Humanized Anti-EGFR AntibodyA2C1. BIT’s 7th Annual International congress of antibodies-2015. April 25-28, Nanjing, China. (Oral Presentation)
XY Yu, WY Qiu, F Long, XP Yang, C Zhang, L Xu, HY Chang, P Du, XJ Hou, YZ Yu, DD Zeng, S Wang, ZW Sun. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. Biochimie 151 (2018): 54 - 66.
Du P, Xu L, Qiu W, Zeng D, Yue J, Wang S, Huang P, Sun Z. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus. MAbs. 2015 Sep 3;7(5):969-80.
Chen L, Li W, Qiu W, Ren W, Li Q, Han B, Zhou L, Cheng L, Zhang H, Ye Q. RSRC1 SUMOylation enhances SUMOylation and inhibits transcriptional activity of estrogen receptor β. FEBS Lett. 2015 Jun 4;589(13):1476-84.